HYTALIF
DEAD

Serial Number

79184536

Owner

NOVARTIS AG

Attorney

Maury M. Tepper, III

Filing Date

Jan 18, 2016

Add to watchlist:

No watchlists yet
View on USPTO

HYTALIF Trademark

Serial Number: 79184536

HYTALIF is a trademark filed by NOVARTIS AG on January 18, 2016. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

NOVARTIS AG (7,173 trademarks)

CH-4002
BASEL , CH

Entity Type: 03

Trademark Details

Filing Date

January 18, 2016

Registration Date

Not Registered

Goods & Services

Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; anti-fungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical products; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastrointestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculoskeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical products for ophthalmological use; pharmaceutical products for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and the treatment of allergies; pharmaceutical products for the prevention and treatment of bone diseases; pharmaceutical products for the prevention and treatment of respiratory diseases and asthma

Filing History

NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED
Nov 16, 2022 DENA
DEATH OF INTERNATIONAL REGISTRATION
Nov 15, 2022 DETH
FINAL DECISION TRANSACTION PROCESSED BY IB
Jul 27, 2018 FINT
FINAL DISPOSITION NOTICE SENT TO IB
Jul 5, 2018 FICS
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jul 5, 2018 FICR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Nov 17, 2017 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Aug 16, 2017 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Aug 16, 2017 OPNR
ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Jul 5, 2017 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Jul 5, 2017 ABN2
NOTIFICATION OF FINAL REFUSAL EMAILED
Nov 28, 2016 GNFN
FINAL REFUSAL E-MAILED
Nov 28, 2016 GNFR
FINAL REFUSAL WRITTEN
Nov 28, 2016 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 4, 2016 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 3, 2016 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 3, 2016 TROA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 26, 2016 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 26, 2016 REAP
REFUSAL PROCESSED BY IB
Jul 2, 2016 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
May 5, 2016 RFCS
REFUSAL PROCESSED BY MPU
May 5, 2016 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
May 5, 2016 RFCR
NON-FINAL ACTION WRITTEN
May 4, 2016 CNRT
ASSIGNED TO EXAMINER
May 2, 2016 DOCK
APPLICATION FILING RECEIPT MAILED
Mar 18, 2016 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 14, 2016 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Mar 11, 2016 LIMI
SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB
Mar 10, 2016 SDRC